Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015

de Bono, 2010, Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial, Lancet, 376, 1147, 10.1016/S0140-6736(10)61389-X Kantoff, 2010, Sipuleucel-T immunotherapy for castration-resistant prostate cancer, N Engl J Med, 363, 411, 10.1056/NEJMoa1001294 de Bono, 2011, Abiraterone and increased survival in metastatic prostate cancer, N Engl J Med, 364, 1995, 10.1056/NEJMoa1014618 Scher, 2012, Increased survival with enzalutamide in prostate cancer after chemotherapy, N Engl J Med, 367, 1187, 10.1056/NEJMoa1207506 Parker, 2013, Alpha emitter radium-223 and survival in metastatic prostate cancer, N Engl J Med, 369, 213, 10.1056/NEJMoa1213755 Ryan, 2013, Abiraterone in metastatic prostate cancer without previous chemotherapy, N Engl J Med, 368, 138, 10.1056/NEJMoa1209096 Beer, 2014, Enzalutamide in metastatic prostate cancer before chemotherapy, N Engl J Med, 371, 424, 10.1056/NEJMoa1405095 Smith, 2012, Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial, Lancet, 379, 39, 10.1016/S0140-6736(11)61226-9 Saad, 2002, A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma, J Natl Cancer Inst, 94, 1458, 10.1093/jnci/94.19.1458 Saad, 2004, Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer, J Natl Cancer Inst, 96, 879, 10.1093/jnci/djh141 Hsu, 2007, The Delphi technique: making sense of consensus, Practical Assess Res Eval, 12, 1 Goldhirsch, 2013, Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013, Ann Oncol, 24, 2206, 10.1093/annonc/mdt303 Tolis, 1982, Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists, Proc Natl Acad Sci USA, 79, 1658, 10.1073/pnas.79.5.1658 Kaisary, 1991, Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma, Br J Urol, 67, 502, 10.1111/j.1464-410X.1991.tb15195.x Vogelzang, 1995, Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group, Urology, 46, 220, 10.1016/S0090-4295(99)80197-6 Klotz, 2008, The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer, BJU Int, 102, 1531, 10.1111/j.1464-410X.2008.08183.x Crawford, 2011, A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer, J Urol, 186, 889, 10.1016/j.juro.2011.04.083 Crawford, 2014, Long-term tolerability and efficacy of degarelix: 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelix, Urology, 83, 1122, 10.1016/j.urology.2014.01.013 Akaza, 2014, Treatment patterns in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (DOC)-based chemotherapy (CTX): PROXIMA, Ann Oncol, 25, iv255 James, 2015, Survival with newly diagnosed metastatic prostate cancer in the “Docetaxel Era”: data from 917 patients in the control arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019), Eur Urol, 67, 1028, 10.1016/j.eururo.2014.09.032 Gleave, 1998, Intermittent androgen suppression for prostate cancer: rationale and clinical experience, Eur Urol, 34, 37, 10.1159/000052297 Akakura, 1993, Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen, Cancer, 71, 2782, 10.1002/1097-0142(19930501)71:9<2782::AID-CNCR2820710916>3.0.CO;2-Z Klotz, 1986, Intermittent endocrine therapy for advanced prostate cancer, Cancer, 58, 2546, 10.1002/1097-0142(19861201)58:11<2546::AID-CNCR2820581131>3.0.CO;2-N Niraula, 2013, Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials, J Clin Oncol, 31, 2029, 10.1200/JCO.2012.46.5492 Huggins, 1945, Bilateral adrenalectomy in prostatic cancer: clinical features and urinary excretion of 17-ketosteroids and estrogen, Ann Surg, 122, 1031, 10.1097/00000658-194512260-00012 Labrie, 1982, New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen, Clin Invest Med, 5, 267 Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials, 2000, Prostate Cancer Trialists' Collaborative Group, Lancet, 355, 1491 Samson, 2002, Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma, Cancer, 95, 361, 10.1002/cncr.10647 Caubet, 1997, Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens, Urology, 49, 71, 10.1016/S0090-4295(96)00325-1 Akaza, 2009, Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival, Cancer, 115, 3437, 10.1002/cncr.24395 Cooperberg, 2014, Trans-pacific variation in outcomes for men treated with primary androgen deprivation therapy for prostate cancer, BJU Int G Gravis, JMBoher, FJolyet al. Androgen deprivation therapy plus docetaxel versus ADT alone for hormone-naive metastatic prostate cancer: long-term analysis of the GETUG-AFU 15 phase III trial. In 2015 Genitourinary Cancers Symposium. Presented 26 February 2015. J Clin Oncol 2015; 33(suppl 7): abstr 140. Gravis, 2013, Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial, Lancet Oncol, 14, 149, 10.1016/S1470-2045(12)70560-0 Sweeney, 2014, Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): an ECOG-led phase III randomized trial, J Clin Oncol, 32 Eisenberger, 1998, Bilateral orchiectomy with or without flutamide for metastatic prostate cancer, N Engl J Med, 339, 1036, 10.1056/NEJM199810083391504 Glass, 2003, Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning, J Urol, 169, 164, 10.1016/S0022-5347(05)64059-1 James, 2015, Docetaxel and/or zoledronic acid for hormone-naïve prostate cancer: first overall survival results from STAMPEDE (NCT00268476), J Clin Oncol, 33 Smith, 2014, Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance), J Clin Oncol, 32, 1143, 10.1200/JCO.2013.51.6500 Schweizer, 2013, Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy, Ann Oncol, 24, 2881, 10.1093/annonc/mdt335 Ost, 2015, Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature, Eur Urol, 67, 852, 10.1016/j.eururo.2014.09.004 Lecouvet, 2012, Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer?, Eur Urol, 62, 68, 10.1016/j.eururo.2012.02.020 Poulsen, 2014, Spine metastases in prostate cancer: comparison of technetium-99m-MDP whole-body bone scintigraphy, [(18) F]choline positron emission tomography(PET)/computed tomography (CT) and [(18) F]NaF PET/CT, BJU Int, 114, 818, 10.1111/bju.12599 Shen, 2014, Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis, Skeletal Radiol, 43, 1503, 10.1007/s00256-014-1903-9 Nelson, 2008, Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer, Cancer, 113, 2478, 10.1002/cncr.23864 Miller, 2013, Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer, Prostate Cancer Prostatic Dis, 16, 187, 10.1038/pcan.2013.2 Smith, 2013, Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time, J Clin Oncol, 31, 3800, 10.1200/JCO.2012.44.6716 Crawford, 2014, Challenges and recommendations for early identification of metastatic disease in prostate cancer, Urology, 83, 664, 10.1016/j.urology.2013.10.026 Small, 2004, Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583), J Clin Oncol, 22, 1025, 10.1200/JCO.2004.06.037 Brasso, 2014, Enzalutamide antitumour activity against metastatic castration-resistant prostate cancer previously treated with docetaxel and abiraterone: a multicentre analysis, Eur Urol Petrelli, 2015, Enzalutamide after docetaxel and abiraterone acetate treatment in prostate cancer: a pooled analysis of 10 case series, Clin Genitourin Cancer, 13, 193, 10.1016/j.clgc.2014.10.006 Cheng, 2015, Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel, Prostate Cancer Prostatic Dis, 18, 122, 10.1038/pcan.2014.53 Noonan, 2013, Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide, Ann Oncol, 24, 1802, 10.1093/annonc/mdt138 Loriot, 2013, Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100), Ann Oncol, 24, 1807, 10.1093/annonc/mdt136 Mezynski, 2012, Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?, Ann Oncol, 23, 2943, 10.1093/annonc/mds119 Suzman, 2014, Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone, Prostate, 74, 1278, 10.1002/pros.22844 Aggarwal, 2013, Cancer, 119, 3636, 10.1002/cncr.28285 Al Nakouzi, 2014, Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies, Eur Urol Pezaro, 2014, Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents, Eur Urol, 66, 459, 10.1016/j.eururo.2013.11.044 Sella, 2014, Activity of cabazitaxel after docetaxel and abiraterone acetate therapy in patients with castration-resistant prostate cancer, Clin Genitourin Cancer, 12, 428, 10.1016/j.clgc.2014.06.007 Pezaro, 2014, Visceral disease in castration-resistant prostate cancer, Eur Urol, 65, 270, 10.1016/j.eururo.2013.10.055 Armstrong, 2012, Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer, Eur Urol, 61, 549, 10.1016/j.eururo.2011.11.009 Scher, 2008, Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group, J Clin Oncol, 26, 1148, 10.1200/JCO.2007.12.4487 Messiou, 2011, The CT flare response of metastatic bone disease in prostate cancer, Acta Radiol, 52, 557, 10.1258/ar.2011.100342 Ryan, 2011, Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response, Clin Cancer Res, 17, 4854, 10.1158/1078-0432.CCR-11-0815 Morris, 2015, Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results, J Clin Oncol, 33, 1356, 10.1200/JCO.2014.55.3875 Wu, 2013, Role of magnetic resonance imaging in the detection of local prostate cancer recurrence after external beam radiotherapy and radical prostatectomy, Clin Oncol (R Coll Radiol), 25, 252, 10.1016/j.clon.2012.11.010 Barchetti, 2014, Multiparametric MRI for recurrent prostate cancer post radical prostatectomy and postradiation therapy, Biomed Res Int, 2014, 316272, 10.1155/2014/316272 Lecouvet, 2014, Monitoring the response of bone metastases to treatment with Magnetic Resonance Imaging and nuclear medicine techniques: a review and position statement by the European Organisation for Research and Treatment of Cancer imaging group, Eur J Cancer, 50, 2519, 10.1016/j.ejca.2014.07.002 Evangelista, 2013, Choline PET or PET/CT and biochemical relapse of prostate cancer: a systematic review and meta-analysis, Clin Nucl Med, 38, 305, 10.1097/RLU.0b013e3182867f3c Bayley, 2001, A prospective study of factors predicting clinically occult spinal cord compression in patients with metastatic prostate carcinoma, Cancer, 92, 303, 10.1002/1097-0142(20010715)92:2<303::AID-CNCR1323>3.0.CO;2-F Venkitaraman, 2007, Detection of occult spinal cord compression with magnetic resonance imaging of the spine, Clin Oncol (R Coll Radiol), 19, 528, 10.1016/j.clon.2007.04.001 Thuret, 2008, The postchemotherapy PSA surge syndrome, Ann Oncol, 19, 1308, 10.1093/annonc/mdn062 Angelergues, 2014, Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer, Eur J Cancer, 50, 1602, 10.1016/j.ejca.2014.03.015 Burgio, 2015, PSA flare with abiraterone in patients with metastatic castration-resistant prostate cancer, Clin Genitourin Cancer, 13, 39, 10.1016/j.clgc.2014.06.010 Tombal, 2005, Magnetic resonance imaging of the axial skeleton enables objective measurement of tumor response on prostate cancer bone metastases, Prostate, 65, 178, 10.1002/pros.20280 Lecouvet, 2013, MRI for response assessment in metastatic bone disease, Eur Radiol, 23, 1986, 10.1007/s00330-013-2792-3 Blackledge, 2014, Assessment of treatment response by total tumor volume and global apparent diffusion coefficient using diffusion-weighted MRI in patients with metastatic bone disease: a feasibility study, PLoS One, 9, e91779, 10.1371/journal.pone.0091779 Padhani, 2014, Therapy monitoring of skeletal metastases with whole-body diffusion MRI, J Magn Reson Imaging, 39, 1049, 10.1002/jmri.24548 Fizazi, 2011, Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study, Lancet, 377, 813, 10.1016/S0140-6736(10)62344-6 Logothetis, 2012, Lancet Oncol, 13, 1210, 10.1016/S1470-2045(12)70473-4 Fizazi, 2014, Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial, Lancet Oncol, 15, 1147, 10.1016/S1470-2045(14)70303-1 Sartor, 2014, Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial, Lancet Oncol, 15, 738, 10.1016/S1470-2045(14)70183-4 Spritzer, 2013, Bone marrow biopsy: RNA isolation with expression profiling in men with metastatic castration-resistant prostate cancer—factors affecting diagnostic success, Radiology, 269, 816, 10.1148/radiol.13121782 Efstathiou, 2012, Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone, J Clin Oncol, 30, 637, 10.1200/JCO.2010.33.7675 Efstathiou, 2015, Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer, Eur Urol, 67, 53, 10.1016/j.eururo.2014.05.005 Ferraldeschi, 2015, PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate, Eur Urol, 67, 795, 10.1016/j.eururo.2014.10.027 Van Allen, 2014, Successful whole-exome sequencing from a prostate cancer bone metastasis biopsy, Prostate Cancer Prostatic Dis, 17, 23, 10.1038/pcan.2013.37 Beltran, 2014, Aggressive variants of castration-resistant prostate cancer, Clin Cancer Res, 20, 2846, 10.1158/1078-0432.CCR-13-3309